More Mesoblast Limited news
Mesoblast LimitedASX: MSB

Mesoblast Initiates Rolling Submission of BLA for GvHD

May 29, 2019 at 11:12 PM EDT · Issued by Mesoblast Limited

Filed with ASX · May 29, 2019 at 11:12 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/mesoblast-initiates-rolling-submission-of-bla-for-gvhd

Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26↗

Mesoblast Limited on 6ix

In the deck

  • Mesoblast — Q3 FY2019 Earnings Presentation43 slidesMay 31, 2019

Story so far

  • Key Day 100 Survival Results In P3 GvHD TrialJun 21, 2018
  • GVHD Day 28 Results PresentationFeb 23, 2018
  • Primary Endpoint Successfully Achieved in MSB P3 GVHD TrialFeb 22, 2018

Earlier from Mesoblast

  • MoU for Confirmatory Trial for GI Bleeding in LVAD PatientsMar 26, 2019
  • MSB Licensee Files For Skin Disease Marketing ApprovalMar 24, 2019
  • MSB Draws US$15 Million From Existing FacilityJan 13, 2019
  • P3 Trial of MSBs Cell Therapy in CHF Completes RecruitmentJan 6, 2019
  • Response to ASX queryDec 5, 2018

Later from Mesoblast

  • MSB Provides Q3 Financial Results and Operational HighlightsMay 30, 2019
  • MSB Expands JCR Partnership To Brain Disease In NewbornsJun 11, 2019
  • FDA Grants Revascor Orphan Drug For End Stage CHF With LVADsJun 24, 2019
  • Circulation Research Highlights MSB Heart Failure TherapyJul 24, 2019
  • Appendix 4C - Quarterly, Strong Commercialization RevenuesJul 31, 2019
All Mesoblast news releases↗

Follow Mesoblast into a list and get an email when it puts out news.

Follow Mesoblast
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer